Home » Zytiga Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Zytiga Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Janssen announced that the European Commission EC has approved an extension to the license of the oral, once-daily medication Zytiga (abiraterone acetate).
Businesswire
Businesswire
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May